VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

PHR.US

24.82

-5.12%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

PHR.US

24.82

-5.12%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

PHR.US

24.82

-5.12%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

PHR.US

24.82

-5.12%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

PHR.US

24.82

-5.12%↓

Search

Medtronic PLC

Geschlossen

BrancheGesundheitswesen

87.86 -1.21

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

87.65

Max

89.31

Schlüsselkennzahlen

By Trading Economics

Einkommen

32M

1.3B

Verkäufe

-111M

8.3B

KGV

Branchendurchschnitt

27.396

63.778

EPS

1.39

Dividendenrendite

3.12

Gewinnspanne

15.798

Angestellte

95,000

EBITDA

-40M

2.4B

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+8.49% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

3.12%

2.39%

Nächstes Ergebnis

22. Mai 2025

Nächste Dividendenausschüttung

11. Apr. 2025

Nächstes Ex-Dividendendatum

27. Juni 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-5.4B

115B

Vorheriger Eröffnungskurs

89.07

Vorheriger Schlusskurs

87.86

Nachrichtenstimmung

By Acuity

28%

72%

68 / 386 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

Medtronic PLC Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

18. Feb. 2025, 12:24 UTC

Ergebnisse

Medtronic 3Q Revenue Rises on Strength in Cardiovascular, Neuroscience

19. Nov. 2024, 12:27 UTC

Ergebnisse

Medtronic Narrows Fiscal Year Guidance as 2Q Tops Views

27. Feb. 2025, 10:30 UTC

Top News

Squeezed by Strong Dollar, Companies Try to Neutralize Currency Swings -- WSJ

18. Feb. 2025, 11:47 UTC

Ergebnisse

Medtronic: Will Accelerate Top-, Bottom-Line Growth in 4Q >MDT

18. Feb. 2025, 11:46 UTC

Ergebnisse

Medtronic Still Sees FY25 Organic Revenue Growth 4.75%-5% >MDT

18. Feb. 2025, 11:45 UTC

Ergebnisse

Medtronic 3Q Adj EPS $1.39 >MDT

18. Feb. 2025, 11:45 UTC

Ergebnisse

Medtronic 3Q Neuroscience Portfolio Rev $2.46B >MDT

18. Feb. 2025, 11:45 UTC

Ergebnisse

Medtronic 3Q Net $1.29B >MDT

18. Feb. 2025, 11:45 UTC

Ergebnisse

Medtronic 3Q Diabetes Rev $694M >MDT

18. Feb. 2025, 11:45 UTC

Ergebnisse

Medtronic 3Q Medical Surgical Portfolio Rev $2.07B >MDT

18. Feb. 2025, 11:45 UTC

Ergebnisse

Medtronic 3Q Cardiovascular Portfolio Rev $3.04B >MDT

18. Feb. 2025, 11:45 UTC

Ergebnisse

Medtronic 3Q Organic Revenue Up 4.1% >MDT

18. Feb. 2025, 11:45 UTC

Ergebnisse

Medtronic 3Q EPS $1.01 >MDT

18. Feb. 2025, 11:45 UTC

Ergebnisse

Medtronic Sees FY Adj EPS $5.44-Adj EPS $5.50 >MDT

18. Feb. 2025, 11:45 UTC

Ergebnisse

Medtronic 3Q Sales $8.29B >MDT

18. Feb. 2025, 10:01 UTC

Ergebnisse
Heiße Aktien

Stocks to Watch Tuesday: Intel, Baidu, Constellation Brands -- WSJ

21. Jan. 2025, 19:15 UTC

Top News

Medtronic Hires CFO From Renault -- Update

21. Jan. 2025, 12:17 UTC

Top News

Medtronic Hires CFO From Renault

19. Nov. 2024, 12:12 UTC

Ergebnisse

Medtronic Narrows FY Guidance as 2Q Tops Views

19. Nov. 2024, 11:46 UTC

Ergebnisse

Medtronic Sees High-Single-Digit Adjusted EPS Growth in 2nd Half of FY25 >MDT

19. Nov. 2024, 11:46 UTC

Ergebnisse

Medtronic Narrows FY25 Organic Rev Growth View to 4.75%-5% From 4.5%-5% >MDT

19. Nov. 2024, 11:45 UTC

Ergebnisse

Medtronic 2Q Medical Surgical Portfolio Rev $2.13B >MDT

19. Nov. 2024, 11:45 UTC

Ergebnisse

Medtronic 2Q Adj EPS $1.26 >MDT

19. Nov. 2024, 11:45 UTC

Ergebnisse

Medtronic 2Q Diabetes Rev $686M >MDT

19. Nov. 2024, 11:45 UTC

Ergebnisse

Medtronic 2Q Neuroscience Portfolio Rev $2.45B >MDT

19. Nov. 2024, 11:45 UTC

Ergebnisse

Medtronic 2Q Net $1.27B >MDT

19. Nov. 2024, 11:45 UTC

Ergebnisse

Medtronic 2Q Organic Revenue Up 5.0% >MDT

19. Nov. 2024, 11:45 UTC

Ergebnisse

Medtronic 2Q Cardiovascular Portfolio Rev $3.1B >MDT

19. Nov. 2024, 11:45 UTC

Ergebnisse

Medtronic Sees FY Adj EPS $5.44-Adj EPS $5.50 >MDT

19. Nov. 2024, 11:45 UTC

Ergebnisse

Medtronic 2Q Sales $8.4B >MDT

Peer-Vergleich

Kursveränderung

Medtronic PLC Prognose

Kursziel

By TipRanks

8.49% Vorteil

12-Monats-Prognose

Durchschnitt 96.4 USD  8.49%

Hoch 109 USD

Tief 85 USD

Basierend auf 19 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Medtronic PLC – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

19 ratings

9

Buy

9

Halten

1

Sell

Technischer Score

By Trading Central

88.02 / 90.29Unterstützung & Widerstand

Kurzfristig

Bullish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Weak Bullish Evidence

Stimmung

By Acuity

68 / 386 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Medtronic PLC

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists; and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat other non-exclusive diseases and conditions; and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, a smart insulin pen system. The company was founded in 1949 and is headquartered in Galway, Ireland.